Wegovy and Mounjaro contain different drugs. This is the most important thing to understand before comparing them, because most of the noise around “Wegovy vs Mounjaro” comes from people conflating the brands with the molecules.
Wegovy contains semaglutide and is FDA-approved for chronic weight management. Mounjaro contains tirzepatide and is FDA-approved for type 2 diabetes only — not weight loss. Using Mounjaro for weight loss is off-label. The FDA-approved weight loss version of tirzepatide is Zepbound.
That said, Mounjaro and Zepbound are the same drug at the same doses. Many patients and providers use Mounjaro off-label for weight loss because it’s sometimes better covered by insurance for people with type 2 diabetes. If you want tirzepatide for weight loss and don’t have diabetes, Zepbound is the correct prescription.
The efficacy comparison comes down clearly in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine: tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide at 72 weeks. That’s a 6.5 percentage point gap — meaningful in clinical terms.
Key takeaways
- Wegovy (semaglutide) is FDA-approved for weight loss. Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes — weight loss use is off-label.
- The same drug as Mounjaro is sold as Zepbound with an FDA weight-loss indication.
- Tirzepatide produces more weight loss than semaglutide: 20.2% vs 13.7% in SURMOUNT-5 head-to-head (72 weeks).
- Real-world data (18,386 adults) confirms: 15% vs 8.3% at 12 months for tirzepatide vs semaglutide.
- Side effects are similar — nausea, diarrhea, vomiting — with comparable discontinuation rates (~6–7%).
- Wegovy has stronger cardiovascular outcome data (SELECT trial). Tirzepatide’s outcomes trial (SURPASS-CVOT) showed CV benefit in T2D but full obesity outcomes data is still accumulating.
- Wegovy self-pay starts at $349/month. Mounjaro/Zepbound self-pay vials start at $299/month through LillyDirect.
- The Wegovy pill (oral semaglutide 25 mg, launched January 2026) adds a needle-free option in the semaglutide family.
What is the difference between Wegovy and Mounjaro?
| Wegovy | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual receptor agonist |
| FDA approval | Weight loss (June 2021) | Type 2 diabetes (May 2022) |
| Weight loss label | On-label | Off-label |
| Maximum weekly dose | 2.4 mg (or 7.2 mg Wegovy HD) | 15 mg |
| Starting dose | 0.25 mg weekly | 2.5 mg weekly |
| Form | Weekly injection or daily pill | Weekly injection |
| Self-pay price | From $349/month | From $299/month (Zepbound vials) |
The mechanism difference is significant. Semaglutide acts on GLP-1 receptors — signaling fullness to the brain and slowing gastric emptying. Tirzepatide acts on both GLP-1 and GIP receptors simultaneously. The added GIP action amplifies appetite suppression, improves insulin sensitivity through a second pathway, and increases energy expenditure. This dual mechanism is the primary reason tirzepatide produces more weight loss.
Wegovy vs Mounjaro: weight loss results
Head-to-head trial: SURMOUNT-5
For years, the Wegovy vs Mounjaro comparison could only be made by looking at separate trials with different populations. In May 2025, the first direct head-to-head trial was published in the New England Journal of Medicine.
SURMOUNT-5: 751 adults with obesity or overweight, no type 2 diabetes, 72 weeks. Randomized to maximum tolerated tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg).
| Outcome | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Average weight loss | 20.2% | 13.7% |
| Absolute kg lost | 22.8 kg | 15.0 kg |
| ≥15% weight loss | 62% | 38% |
| ≥20% weight loss | 46% | 20% |
| ≥25% weight loss | 32% | 16% |
Tirzepatide won on every measure. The gap at the ≥25% threshold is the most striking: twice as many tirzepatide patients lost a quarter or more of their body weight.
Real-world comparison (18,386 patients)
A 2025 study using real-world data from 18,386 adults on tirzepatide or semaglutide confirmed the trial results in a broader population:
| Timepoint | Tirzepatide | Semaglutide |
|---|---|---|
| 3 months | 5.9% weight loss | 3.6% |
| 6 months | 10.0% | 5.8% |
| 12 months | 15.0% | 8.3% |
The real-world gap is actually larger than the trial gap, likely because the trial used maximum tolerated doses while real-world prescribing often uses lower maintenance doses.
Side effects: how they compare
Wegovy and Mounjaro share the same side effect profile — this makes sense because both work through the GLP-1 pathway. Gastrointestinal effects are the most common and are most pronounced during dose escalation.
| Side effect | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Nausea | ~44% | ~24–33% |
| Diarrhea | ~30% | ~17–22% |
| Vomiting | ~24% | ~9–13% |
| Constipation | ~24% | ~11–17% |
| Discontinuation | ~6.9% | ~6.2% |
Wegovy shows higher GI side effect rates, probably because semaglutide more potently slows gastric emptying through the GLP-1 pathway alone. Tirzepatide’s GIP component may partially offset this. Despite the higher symptom rates, discontinuation rates are nearly identical — meaning most people who start Wegovy work through the side effects.
Both carry the same boxed warning: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2) are contraindications. Both can cause pancreatitis, gallbladder disease, and acute kidney injury in rare cases.
Cardiovascular outcomes: where Wegovy has an edge
This is the one area where Wegovy has a genuine clinical advantage over Mounjaro — and it matters for some patients.
- Wegovy (semaglutide): The SELECT trial (2024) confirmed that semaglutide reduces major adverse cardiovascular events — heart attack, stroke, cardiovascular death — in adults with established cardiovascular disease and obesity but no diabetes. This gave Wegovy a cardiovascular risk reduction FDA indication in March 2024. For a patient with previous heart attack or stroke and a weight problem, this data is clinically meaningful.
- Mounjaro (tirzepatide): The SURPASS-CVOT trial showed tirzepatide reduces cardiovascular events versus dulaglutide in patients with type 2 diabetes. However, this is not the same as the Wegovy SELECT data — it compared tirzepatide to another GLP-1, not to placebo, in a different population. The tirzepatide obesity-specific cardiovascular outcomes trial (SURMOUNT-MMO) is still running.
For a patient with established cardiovascular disease choosing between the two, prescribers may reasonably prefer Wegovy based on the deeper, more specific outcome data — even though tirzepatide likely has cardiovascular benefits too.
Wegovy vs Mounjaro cost in 2026
| Wegovy | Mounjaro / Zepbound | |
|---|---|---|
| List price | ~$1,349/month | ~$1,086/month |
| Self-pay (starter dose) | $349/month (NovoCare vials) | $299/month (LillyDirect vials) |
| With commercial insurance + savings card | $25/month | $25/month |
| With Wegovy pill option | $149/month (starter) | – |
| Medicare coverage (weight loss) | GLP-1 Bridge from July 2026 | GLP-1 Bridge from July 2026 |
Mounjaro/Zepbound is cheaper for uninsured self-pay patients because LillyDirect sells vials starting at $299/month. Wegovy self-pay through NovoCare starts at $349/month. The gap narrows at higher doses.
With commercial insurance and manufacturer savings cards, both cost as little as $25/month for eligible patients.
One significant Wegovy advantage for budget-conscious patients: the Wegovy pill (oral semaglutide 25 mg, launched January 5, 2026) starts at $149/month self-pay. If 13–16% average weight loss is sufficient for your goals and you prefer a lower cost or no injection, the Wegovy pill is the more affordable option in the semaglutide family. See our full Wegovy pill vs injection comparison.
Which should you choose?
Choose Wegovy (semaglutide) if:
- You have established cardiovascular disease or history of heart attack/stroke (SELECT trial data supports this)
- You want an oral option — the Wegovy pill is available from $149/month
- Your insurance covers Wegovy but not Zepbound
- You’ve previously tried and tolerated semaglutide (Ozempic) and want to continue with the higher weight-loss dose
- Cost is a significant concern and the Wegovy pill price is appealing
Choose Mounjaro or Zepbound (tirzepatide) if:
- Maximum weight loss is your primary goal — tirzepatide consistently produces more
- You have type 2 diabetes alongside obesity (tirzepatide showed superior HbA1c reduction in SURPASS-2)
- You tolerated tirzepatide before but switched to semaglutide and found it less effective
- Zepbound is on your insurance formulary
- Self-pay and LillyDirect’s $299/month starting price works for your budget
The honest answer for most patients: if the primary goal is weight loss and both drugs are accessible, the clinical evidence favors tirzepatide. The 6.5 percentage point gap in the head-to-head trial is real and clinically significant. But Wegovy is a good drug that helps most people who take it, has a longer track record, and is the right choice in specific clinical situations.
Can you switch between Wegovy and Mounjaro?
Yes. Switching between the two is common — insurance changes, tolerability issues, and plateaus all drive switches.
- Switching from Wegovy to Mounjaro (or Zepbound): Stop semaglutide. Start tirzepatide at 2.5 mg the following week. Titrate through the standard schedule regardless of how high a Wegovy dose you were on. The molecules are different and don’t have equivalent doses per milligram.
- Switching from Mounjaro to Wegovy: Stop tirzepatide. Start Wegovy at 0.25 mg the following week. Work through the standard 16-week semaglutide titration. Some providers may start at a higher step if the patient was well-established on a high tirzepatide dose, but this requires clinical judgment.
A full guide on switching between semaglutide and tirzepatide is available in our tirzepatide vs semaglutide comparison.
Conclusion
Tirzepatide (Mounjaro, Zepbound) produces more weight loss than semaglutide (Wegovy) — the SURMOUNT-5 head-to-head trial settled that debate with 20.2% vs 13.7% at 72 weeks. For most patients whose primary goal is maximum weight loss, the evidence favors tirzepatide.
Wegovy remains the better-evidenced choice for patients with established cardiovascular disease, where the SELECT trial data is specific and deep. It also has the oral pill option that tirzepatide doesn’t, and a longer real-world safety record.
The right drug is the one that fits your health profile, insurance, and goals. Book a free consultation with Heally to talk through both options with a licensed provider and get a prescription for whichever fits best — same-day telehealth, prescription delivered to your door.
FAQ
Is Mounjaro better than Wegovy for weight loss?
By clinical trial data, yes. The SURMOUNT-5 head-to-head trial showed tirzepatide (the drug in Mounjaro and Zepbound) produced 20.2% average weight loss versus 13.7% for semaglutide (Wegovy) at 72 weeks. Real-world data confirms the gap.
Is Mounjaro approved for weight loss?
No. Mounjaro is FDA-approved for type 2 diabetes only. Using it for weight loss is off-label. The FDA-approved version of the same drug (tirzepatide) for weight loss is Zepbound, approved November 2023.
What is the difference between Mounjaro and Zepbound?
They are the same drug — tirzepatide — at the same doses. Mounjaro is the brand name for the type 2 diabetes indication. Zepbound is the brand name for the weight management and sleep apnea indication. If you want insurance to cover tirzepatide for weight loss, you need a Zepbound prescription, not Mounjaro.
What is the difference between Wegovy and Ozempic?
Both contain semaglutide. Wegovy is dosed higher (2.4 mg or 7.2 mg weekly) and is FDA-approved for weight loss. Ozempic is dosed up to 2.0 mg weekly and is FDA-approved for type 2 diabetes. Wegovy produces more weight loss than standard Ozempic doses because the dose is higher.
Does Wegovy or Mounjaro have fewer side effects?
Side effect rates are slightly lower with Mounjaro — nausea affects ~24–33% of Mounjaro users versus ~44% on Wegovy. But discontinuation rates are similar: ~6.2% for tirzepatide, ~6.9% for semaglutide. Most people work through the early GI side effects on both drugs.
Can I take Wegovy and Mounjaro together?
No. These are both GLP-1 medications and should never be used simultaneously. Combining them would cause severe GI side effects and create unpredictable cardiovascular effects. If you’re switching, stop one before starting the other.
Which is cheaper — Wegovy or Mounjaro?
Mounjaro/Zepbound is slightly cheaper for self-pay patients through LillyDirect ($299/month for starter vials vs $349/month for Wegovy). With commercial insurance and savings cards, both cost as little as $25/month. The Wegovy pill starts at $149/month self-pay for patients who want an oral option.
How do I know if I should switch from Wegovy to Mounjaro?
Common reasons to switch: plateaued weight loss on Wegovy, better insurance coverage for Zepbound (tirzepatide’s weight loss brand), or wanting the higher-efficacy drug based on SURMOUNT-5 data. Talk to your provider before switching — the switch requires re-titration from the lowest tirzepatide dose.
Related reading on Heally:
- Zepbound vs Wegovy: complete weight loss comparison
- Zepbound vs Ozempic: weight loss, cost, and key differences
- How to get tirzepatide with insurance: a complete 2026 guide
- Semaglutide in 2026: usage trends and which brands lead
Sources
- NEJM — SURMOUNT-5: tirzepatide vs semaglutide for overweight or obesity (Garvey et al., 2025)
- NEJM — Tirzepatide once weekly for the treatment of obesity, SURMOUNT-1 (2022)
- NEJM — Once-weekly semaglutide in adults with overweight or obesity, STEP 1 (2021)
- NEJM — Semaglutide and cardiovascular outcomes in obesity without diabetes, SELECT trial (2023)
- Medical News Today — Wegovy vs Mounjaro: results, cost, side effects, and risks (updated July 2026)
- FDA — Wegovy (semaglutide) prescribing information, 2025
- FDA — Mounjaro (tirzepatide) prescribing information
Medical disclaimer: This article is for informational purposes only. Mounjaro is FDA-approved for type 2 diabetes only — using it for weight loss is off-label. All prescribing decisions should be made by a licensed healthcare provider based on your individual health profile. Individual results vary.